skip to Main Content

Real-World Data

Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. Explore our real-world data analyses to support your strategic decisions.

John Neal

New Data Approaches for Novel Curative Therapies and APMs

On June 9, Avalere experts discussed new data analytics and approaches for evaluating value-based topics in healthcare in the “New Data Approaches for Novel Curative Therapies & APMs” webinar. They examined the current approaches to assessing the value of treatments, novel curative therapy affordability and access, and the role of data in healthcare decision-making.

Emily Belowich

Chronic Disease Mobile Health Apps Need Better Value Propositions and Evidence

Rising healthcare costs and the increased prevalence of chronic disease in the US are incentivizing stakeholders to develop new solutions to tackle these issues. Many have turned to digital health innovations like mobile health applications to facilitate care prevention and management for chronic disease, but significant gaps remain in their ability to be used in real-world practice.

Medication Adherence Rates Low Among Patients with Serious Mental Illness

Avalere research recently published in ClinicoEconomics and Outcomes Research compared patient characteristics and real-world outcomes in 2 distinct high-risk cohorts of patients with serious mental illness (SMI), including patients with a hospitalization related to SMI (recently discharged) and patients newly diagnosed with SMI (early episode). The research included 51,705 patients with bipolar disorder, major depressive disorder, and schizophrenia.

Manuel Aviña

An Opportunity for Remote Patient Monitoring as Part of Healthcare Delivery for Neurological Care

Remote patient monitoring (RPM) provides an opportunity to diagnose and treat patients facing neurological diseases. Given that multiple sclerosis (MS), Parkinson’s disease, and epilepsy require intervention from specialized care teams, effective management of these chronic neurological conditions can be supported through RPM to improve patient outcomes. Although RPM has been shown to be a complement and in some cases an alternative to office-based care, reimbursement and coverage barriers remain.

Karl Kilgore

Avalere Presents First Real-World Evidence on Medicare Patients’ CAR-T Experiences at ASH Press Briefing

On Saturday, December 7, Karl Kilgore discussed “Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs” during a press briefing at the American Society of Hematology’s Annual Meeting.

Back To Top